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Muscle represents an attractive target tissue for adeno-
associated virus (AAV) vector–mediated gene transfer for 
hemophilia B (HB). Experience with direct intramuscular 
(i.m.) administration of AAV vectors in humans showed 
that the approach is safe but fails to achieve therapeu-
tic efficacy. Here, we present a careful evaluation of the 
safety profile (vector, transgene, and administration pro-
cedure) of peripheral transvenular administration of AAV-
canine factor IX (cFIX) vectors to the muscle of HB dogs. 
Vector administration resulted in sustained therapeutic 
levels  of  cFIX  expression.  Although  all  animals  devel-
oped a robust antibody response to the AAV capsid, no 
T-cell responses to the capsid antigen were detected by 
interferon  (IFN)-γ  enzyme-linked  immunosorbent  spot 
(ELISpot). Interleukin (IL)-10 ELISpot screening of lym-
phocytes  showed  reactivity  to  cFIX-derived  peptides, 
and restimulation of T cells in vitro in the presence of 
the identified cFIX epitopes resulted in the expansion of 
CD4+FoxP3+IL-10+  T-cells.  Vector  administration  was 
not associated with systemic inflammation, and vector 
spread to nontarget tissues was minimal. At the local 
level, limited levels of cell infiltrates were detected when 
the  vector  was  administered  intravascularly.  In  sum-
mary, this study in a large animal model of HB dem-
onstrates that therapeutic levels of gene transfer can be 
safely achieved using a novel route of intravascular gene 
  transfer to muscle.
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IntroductIon
Adeno-associated virus (AAV) vectors can direct efficient gene 
transfer into a variety of target tissues.1–6 Among these, muscle is 
a key target for gene transfer strategies directed to the treatment 
of neuromuscular7 and metabolic diseases,8 and for hemophilia B 
(HB) when liver is compromised due to viral hepatitis.9,10 Direct 
intramuscular (i.m.) administration has been extensively stud-
ied in experimental animals and humans.5,8,11–15 In HB subjects, 
direct i.m. administration of an AAV-2 vector encoding human 
factor IX (FIX) resulted in long-term expression of the transgene, 
which was detectable in muscle sections >3 years after gene trans-
fer.1 However, this delivery method failed to reach therapeutic 
levels of FIX in the circulation, even at a dose of ~2 × 1012 vector 
genomes (vg)/kg (refs. 11,12). The poor performance of AAV-2 
vectors  in  reaching  large  areas  of  muscle  when  injected  i.m. 
may also be associated with higher transgene immunogenicity. 
Importantly, and directly related to the delivery method,16 high 
levels of expression achieved locally (i.e., high antigen concentra-
tion around the injection site) may enhance the risk of immune 
responses to the transgene product;17,18 this holds true particularly 
for proinflammatory environments, such as dystrophic muscle, 
which constitute a danger signal per se.19 In the setting of genetic 
disease, lack of tolerance to the product of the donated gene may 
be associated with unwanted immune responses, resulting in loss 
of therapeutic efficacy. Although AAV gene transfer to liver is 
associated with induction of tolerance to the transgene product20 
mediated by regulatory T-cells,2,21 there is no evidence that AAV-
directed muscle gene transfer is associated with regulatory T-cells 
expansion.22–24 Another important aspect of AAV-mediated gene 
transfer is the T-cell response to the vector capsid; this issue 
emerged recently in the context of liver-directed gene transfer,25,26 
in which transgene expression in human subjects with HB was 
detected only transiently after AAV-2 gene transfer for FIX, due to 
a capsid-specific CD8+ T-cell response that resulted in clearance 
of transduced hepatocytes. Similar findings were also described 
in the context of i.m. gene transfer;5,27 although the role of T-cell 
responses to the AAV capsid is still under study, data suggest that 
dose-dependent activation of capsid T-cell responses may limit 
the duration of the therapeutic transgene expression after both 
intravascular or i.m. gene transfer, with responses less marked 
in healthy muscle tissue where class I expression is usually low 
[although recently published data in a clinical trial of AAV-1 
gene transfer in patients with limb-girdle muscular dystrophy 
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type 2B (α-sarcoglycan deficiency) documented upregulation of 
major   histocompatibility complex class I expression on muscle 
fibers at sites of direct injection of AAV-1; ref. 6].
We showed that regional intravascular delivery using vaso-
active drugs to achieve AAV vector extravasation through the 
vascular endothelium results in sustained expression of the cFIX 
transgene in HB dogs.28 More recently, using afferent transvenu-
lar retrograde extravasation (ATVRX) in the same dog model 
we achieved sustained correction of the HB disease   phenotype.29 
Using  pressure  instead  of  pharmacological  intervention  to 
increase vascular permeability, we achieved canine FIX (cFIX) 
transgene  expression  levels  up  to  tenfold  higher  than  those 
measured with the same vector and dose, delivered by direct 
i.m.  injection.13  For  both  regional  intravascular  and  ATVRX 
vector delivery, transient immunosuppression (IS) was needed 
to prevent antibody responses to the cFIX donated gene product 
in hemophilic dogs.
In this study, we present the complete characterization of the 
safety profile of ATVRX delivery of AAV vectors encoding the 
cFIX transgene in HB dogs. We show that AAV vector deliv-
ery of the cFIX transgene to muscle via ATVRX under transient 
immunosuppression is associated with (i) limited, non-neutral-
izing antibody responses to the cFIX transgene characterized by 
almost exclusive production of IgG2 antibodies; (ii) absence of 
T-cell responses to the AAV capsid; (iii) secretion of interleu-
kin (IL)-10 at high levels in response to cFIX antigen or cFIX-
derived peptides in circulating peripheral blood mononuclear 
cells  (PBMCs),  and  expansion  of  a  population  of  CD4+IL-
10+FoxP3+ T-cells in response to cFIX antigen; (iv) minimal 
systemic or local inflammation; and (v) minimal vector trans-
duction of nontarget tissues. Together, these data support the 
safety of ATVRX vector administration for the correction of the 
HB disease phenotype.
results
AtVrX administration of AAV vectors  
to the muscle of HB dogs under Is results  
in sustained expression of the cFIX transgene
The safety of AAV-mediated muscle gene transfer via ATVRX30 
was evaluated in a large cohort of HB dogs (Table 1) carrying a 
missense mutation in the cFIX gene (University of North Carolina 
at Chapel Hill colony). HB dogs received 1 × 1012 vg/kg (low dose, 
n = 2), 3 × 1012 vg/kg (mid-dose, n = 3), or 8.5 × 1012 vg/kg (high 
dose, n = 2) of an AAV-2-cFIX vector via ATVRX under transient 
IS with cyclophosphamide. As controls, four HB dogs received 
3 × 1012 vg/kg of the same vector via ATVRX (n = 2) or i.m. 
(n = 2) without IS (Table 1). Two additional HB dogs received 3 × 
1012 vg/  kg of an AAV-6-cFIX vector via ATVRX with IS. ATVRX 
delivery of the AAV-2-cFIX vector in HB dogs resulted in pla-
teau plasma levels of cFIX transgene product ranging from ~80 
to ~275 ng/ml at a dose of 3 × 1012 vg/kg, compared to ~10 ng/ml 
of circulating cFIX obtained when the same vector at the same 
dose was delivered i.m. (compare group B to group E in Table 1). 
A further dose advantage was obtained by switching to an AAV 
serotype 6 vector (Table  1). Efficacy of ATVRX delivery in HB 
dogs is discussed elsewhere.29
No  postphlebitic  syndrome  or  postprocedure  angiopa-
thy has been noted in any of the animals. Transient IS, given 
around the time of ATVRX administration of the vector in HB 
dogs, efficiently prevented inhibitory antibody responses to the 
cFIX transgene product at vector doses up to 3 × 1012 vg/kg. 
However, at a vector dose of 8.5 × 1012 vg/kg, declining cFIX 
transgene expression levels were observed even under IS, and 
the  formation  of  non-neutralizing  IgG2  antibodies  to  cFIX 
was documented by enzyme-linked immunosorbent assay and 
western blot shortly after IS discontinuation. ATVRX admin-
istration of 3 × 1012 vg/kg of the AAV-2-cFIX vector with no 
table 1  summary of experimental design and cFIX expression data
experimental group and vector dose dog Id serotype route Is
circulating  
cFIXa (ng/ml)
Anti-cFIX IgG  
antibody response
Inhibitor  
(peak Bu)
A—low dose IS: 1 × 1012 vg/kg I04 AAV-2 ATVRX Y 32 ± 7 − N
I05 AAV-2 ATVRX Y 141 ± 18 +/− (IgG2) N
J04 AAV-2 ATVRX Y 27 ± 4 − N
B—mid-dose IS: 3 × 1012 vg/kg I07 AAV-2 ATVRX Y 125 ± 39 +/− (IgG2) N
H34 AAV-2 ATVRX Y 76 ± 14 +/− (IgG2) N
H48 AAV-2 ATVRX Y 275 ± 75 − N
C—high dose IS: 8.5 × 1012 vg/kg H24 AAV-2 ATVRX Y 20 ± 3 + (IgG2)b N
M25 AAV-2 ATVRX Y 23 ± 3 + (IgG2)b N
D—Mid-dose no IS: 3 × 1012 vg/kg J03 AAV-2 ATVRX N 81 ± 13 + (IgG2) N
J62 AAV-2 ATVRX N 120c ++ (IgG2 > IgG1) Y (1.5)
E—Mid-dose i.m. no IS: 3 × 1012 vg/kg M14 AAV-2 i.m. N 11 ± 0.1 +/− (IgG2) N
M24 AAV-2 i.m. N 10 ± 0.1 − N
F—mid-dose AAV-6 IS: 3 × 1012 vg/kg M13 AAV-6 ATVRX Y 259 ± 37 − N
M20 AAV-6 ATVRX Y 213 ± 25 − N
Abbreviations: AAV, adeno-associated virus; ATVRX, afferent transvenular retrograde extravasation; BU, Bethesda units; cFIX, canine factor IX; i.m., intramuscular; 
IS, immunosuppression; N, no; Y, yes.
aMean ± SD of at least three measurements >2–4 months post-treatment; bConfirmed by western blot; cAfter inhibitor eradication.1320  www.moleculartherapy.org  vol. 18 no. 7 july 2010     
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concomitant  administration  of  cyclophosphamide  resulted 
in the   development of a neutralizing antibody to the cFIX in 
one  animal  (J62),  peaking  at  1.5  Bethesda  units  and  slowly 
disappearing over time; in this dog, antibody subclass analysis 
showed the production of both IgG1 and IgG2, with the titer 
for IgG2 > IgG1. None of the other HB injected dogs devel-
oped neutralizing anti-cFIX antibodies; however, several dogs 
developed low-titer (<1,000 ng/ml) non-neutralizing IgG2 anti-
bodies >3 months after vector administration (Table 1). These 
antibodies did not seem to affect the levels of circulating cFIX 
transgene product (Table 1).
We next undertook a complete evaluation of local and   systemic 
immune responses in these experimental groups.
Intravascular or i.m. AAV vector administration 
results in IgG2 anti-capsid antibody formation  
but no capsid-triggered IFn-γ secretion detected  
by elIspot
All naive animals had no detectable anti-AAV antibodies before 
vector administration. Following gene transfer, all animals devel-
oped  high-titer  antibodies  to  the  AAV  capsid  (Figure  1).  No 
significant difference in the titer was observed among the experi-
mental groups, except for a ~twofold higher titer measured in 
the mid-dose ATVRX dogs compared to dogs injected i.m. with 
the same vector and dose (3 × 1012 vg/kg), probably reflecting the 
more extensive systemic exposure to the vector. Anti-AAV anti-
body subclass analysis showed the prevalence of a Th2 response, 
characterized by the secretion of IgG2 (Figure 1b), with limited 
secretion of IgG1 (Figure 1a). Similar differences in relative titers 
of IgG subclasses were noted in dogs receiving AAV-1 or AAV-6 
i.m. or via ATVRX, respectively (data not shown).
A capsid-specific interferon (IFN)-γ enzyme-linked immuno-
sorbent spot (ELISpot) assay was used to follow T-cell responses 
to the AAV capsid. For antigen stimulation, a peptide library of 
15-mers overlapping in sequence by 10 amino acids and spanning 
the sequence of the VP-1 capsid protein was used for the screen-
ing; alternatively, purified AAV empty capsids were also used. No 
T-cell responses to the AAV capsid were detected at baseline or 
at any time point tested in the dogs in the study (Supplementary 
Table  S1).  These  results  were  also  confirmed  in  HB  dogs 
  re-administered with an AAV-2 or an AAV-6 vector expressing 
the cFIX transgene via ATVRX (data not shown).
To test whether alternate AAV serotypes with higher tropism 
for muscle tissue than AAV-2 were more immunogenic, we also 
injected a normal dog (J53) i.m. with an AAV-1-null vector (J53) 
and monitored T-cell responses to the capsid by IFN-γ ELISpot; 
similar to the other animals, no response was detectable at any 
time point in J53 (Supplementary Table S1).
t-cell responses to the cFIX transgene product  
are characterized by secretion of Il-10 detected  
in an elIspot assay.
T-cell responses directed to the cFIX transgene were analyzed by 
IFN-γ and IL-10 ELISpots to detect antigen-specific Th1 and Th2 
responses, respectively. No IFN-γ responses to peptides derived 
from cFIX were detected at any time (Supplementary Table S1), 
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Figure 2  time course of Il-10 elIspot responses to canine FIX (cFIX) in dogs receiving AAV-2-cFIX vectors by AtVrX. Secretion of IL-10 from 
PBMCs after stimulation with peptides spanning the cFIX sequence organized in 19 pools. Samples were collected and analyzed at baseline, during 
IS and after IS discontinuation. Responses were considered positive when the number of spot-forming units (SFU) per million PBMCs were >50 and at 
least threefold higher than the media control (Med). All test conditions were assayed in triplicate. (a) Group A (1 × 1012 vg/kg with IS); (b) Group B 
(3 × 1012 vg/kg with IS); (c) Group C (8.5 × 1012 vg/kg with IS); (d) Group D (3 × 1012 vg/kg without IS). Baseline sample for J62 was not available; a 
sample obtained 1 week after vector delivery was analyzed instead. ATVRX, afferent transvenular retrograde extravasation; IL, interleukin; IS, immuno-
suppression; PBMC, peripheral blood mononuclear cell.
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consistent with the results of anti-cFIX antibody subclass analy-
sis  showing  prevalent  secretion  of  non-neutralizing  anti-cFIX 
IgG2 antibodies (Table 1). Absence of IFN-γ response to the cFIX 
transgene product was also documented in dog J62 although the 
inhibitor to cFIX persisted (Table 1).
An IL-10 ELISpot assay was used to monitor Th2 responses 
triggered by the cFIX transgene product. A library of peptides 
(15-mers overlapping by 10 amino acids in sequence) was designed 
based on the wild-type cFIX sequence and organized in 19 pools 
to form a matrix as previously described.26 We analyzed PBMCs 
collected from the animals in experimental groups A–D (Table 1) 
at baseline, during IS administration, and after IS discontinuation. 
All dogs showed some level of reactivity to cFIX peptide pools 
(Figure 2); at baseline, 3/8 animals tested showed a marked IL-10 
ELISpot response to cFIX [>400 spot-forming units/106 PBMCs] 
while the remaining animals had either a lower or no response 
at baseline. In some of the animal tested, IS administration was 
associated with a marked decrease in the IL-10 response to cFIX 
(Figure 2, dogs I04, I05, and H34), which then returned to detect-
able levels after IS discontinuation. Analysis of reactive pools 4 and 
17, the two pools which scored consistently positive in most of the 
IL-10 ELISpot assays, led to the identification of a peptide epitope 
candidate, peptide 68 (Figure 3a). We further investigated the pep-
tides contained in pool 4 by rearranging them into smaller pools 
(Figure 3b) and testing these pools in the IL-10 ELISpot assay. 
With  this  approach,  we  showed  reactivity  for  another  peptide 
within cFIX, peptide 84 (Figure 3c), in one of the two dogs receiv-
ing the highest dose of vector (8.5 × 1012 vg/kg) via ATVRX (H24). 
Of note, the peptide (84 amino acids) sequence spans the cFIX 
Chapel Hill mutation responsible for HB in this dog colony.31
Il-10 responses to cFIX are associated with expansion 
of a population of cd4+Il-10+FoxP3+ t-cells
IL-10 responses to the cFIX antigen were detectable by ELISpot in 
naive HB dogs tested with both the cFIX pepide library (Figure 2) 
and cFIX whole protein (Figure 4a). The detection of cFIX in the 
liver lysate of these dogs (Figure 4a) may explain why HB dogs 
do have responses to the protein even in the absence of circulat-
ing cFIX. We further investigated the role of IL-10 secretion in 
response to cFIX pool 4, the pool that scored positive for most 
of the animals tested. PBMCs collected between week 10 and 12 
(after IS discontinuation) from dogs H34 and H48 (AAV-2-cFIX, 
3 × 1012 vg/kg via ATVRX with IS), and dogs J03 and J62 (AAV-2-
cFIX, 3 × 1012 vg/kg via ATVRX without IS) were cultured in vitro 
with an irrelevant cFIX peptide pool, serving as negative control, 
peptide 68, or purified cFIX protein. After a 7-day stimulation in 
the presence of canine IL-2 and antigen, a population of CD4+ 
T-cells expressing IL-10 was detectable to some extent in all ani-
mals  for  all  restimulation  conditions  (Figure  4b,  left  panels). 
FoxP3 staining of CD4+IL-10+ T-cells showed a marked difference 
between the animals which received the vector under IS (H34 and 
H48) and those which did not (J03 and J62), with the detection 
of a population of CD4+IL-10+FoxP3+ T-cells only in dogs H34 
and H48 and only in response to restimulation with cFIX pro-
tein or peptide 68, but not with the negative control (Figure 4b, 
right panels). When assayed for suppressor activity, cFIX or pep-
tide 68 expanded cells induced a slight reduction (compared to 
mock-stimulated PBMCs) in secretion of IFN-γ from autologous, 
unexpanded CD4+ T-cells activated with an anti-CD3 antibody 
(data not shown).
Bioinformatics analysis of peptide 68 using a major histocom-
patibility complex class II binding model developed for human 
alleles32 showed that the N-terminal 9 amino acids of this pep-
tide (FLKFGSGYV) have high binding affinity for several human 
leukocyte  antigen  alleles.  This  binding  promiscuity  potentially 
explains why the same peptide scored positive in several outbred 
animals.
AAV-mediated gene transfer to muscle via AtVrX  
is associated with minimal systemic inflammation
Serum samples collected at baseline and at day 1, 3, 21, and 60 
after ATVRX gene transfer from animals in experimental groups 
B (H34, AAV-2-cFIX, 3 × 1012 vg/kg with IS), C (M25, AAV-2-
cFIX, 8.5 × 1012 vg/kg with IS), D (J62, AAV-2-cFIX, 3 × 1012 vg/kg 
without IS), and F (M13, AAV-6-cFIX, 3 × 1012 vg/kg with IS) were 
assayed for cytokine and chemokine secretion in a luminex-based 
assay (Figure 5). Fourteen analytes, including markers of innate 
and adaptative immune responses, were included in the screening. 
None of the dogs showed secretion of early inflammation   markers 
like IL-6 or TNF-α at any point after gene transfer. An elevation 
of  IL-8  and  keratinocyte-derived  chemokine  was  measured  in 
most of the dogs tested; these two markers are typically associ-
ated with vascular damage and remodeling,33,34 and their detection 
early after ATVRX delivery of vector may reflect vascular damage/
stress from the procedure itself rather than from exposure to AAV. 
J62, the HB dog that developed an inhibitor after vector admin-
istration without IS, had high levels of circulating IL-7, perhaps 
reflecting the ongoing, Th1-driven immune response to cFIX.
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Biodistribution of AAV vector genome  
following AtVrX delivery shows vector is found  
predominantly in the muscle of the target limb
Two hemostatically normal dogs were used to perform vector 
biodistribution studies. The animals received 8.5 × 1012 vg/kg of 
an AAV-2-cFIX vector via ATVRX and were killed 20 weeks after 
gene transfer. Genomic DNA was extracted from several tissues, 
including muscle collected at different sites in the target and con-
tralateral limbs. For the real-time quantitative PCR used in the 
assay, a probe placed across a splice junction in cFIX was used 
to  ensure  that  the  reaction  would  not  amplify  genomic  DNA 
but only the donated gene. Results of biodistribution studies are 
shown in Figure 6. Widespread muscle transduction was detected 
in the target limb, whereas minimal muscle transduction was evi-
dent in the contralateral leg. Little or no PCR signal was evident 
in other organs, with the exception of liver, spleen, and kidneys. 
This result reflects the systemic exposure to the AAV vector and 
is in agreement with previous studies of AAV-2 gene transfer to 
liver in nonhuman primates,2 in which the same vector dose was 
given through the hepatic artery, showing prevalent vector dis-
tribution to spleen and liver, with no altered tropism related to 
IS administration. Although it is not clear which splenocyte cell 
subpopulation(s) was mainly positive for AAV vector genomes, 
no enhanced immune responses to either the vector capsid or the 
transgene product, or both, were evident compared to other routes 
of vector administration targeting the muscle or the liver.1,2,13,35 
This may reflect the poor immunogenic profile of AAV vectors, at 
least in experimental animal models.36,37
AtVrX delivery of AAV vectors is associated  
with limited muscle alterations
We have shown that ATVRX delivery of an AAV-2-cFIX vector 
to muscle of HB dogs results in detection of cFIX locally in trans-
duced muscle tissue.29 Here, we evaluated the histology of muscle 
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biopsies from ATVRX-injected dogs from experimental groups 
B—mid-dose AAV-2 (3 × 1012 vg/kg with IS, H48, I07), C—high 
dose AAV-2 (8.5 × 1012 vg/kg with IS, M25), and F—mid-dose 
AAV-6 (3 × 1012 vg/kg with IS, M13) collected ~6 months after 
gene  transfer.  Muscle  biopsies  from  dog  M14,  which  received 
an AAV-2-cFIX vector i.m. at 3 × 1012 vg/kg, were also analyzed. 
Hematoxylin and eosin staining of muscle sections were free of 
muscle alterations in dogs I07 (Figure 7a), M25 (Figure 7c), and 
M13 (Figure 7d), a result consistent with all other end points 
analyzed in the study (IFN-γ ELISpot for AAV capsid and trans-
gene product, luminex assay for cytokines, and cFIX transgene 
expression). In contrast to these results, muscle sections collected 
at the same time from one of the dogs receiving 3 × 1012 vg/kg of the 
AAV-2-cFIX vector, H48, showed evidence of muscle inflamma-
tion and regeneration in the semi-tendinosus muscle (Figure 7b). 
Similarly, the HB dog injected i.m. with the same vector, M14, had 
signs of local inflammation at the vector injection sites (Figure 7e). 
Of note, cellular infiltrates in dog H48 were detectable only in one 
of the muscles analyzed (Figure 7b) and did not interfere with 
cFIX transgene expression. No signs of muscle inflammation or 
regeneration were evident in animal M13, which received 3 × 
1012 vg/kg of an AAV-6-cFIX vector (Figure 7d). Immunostaining 
of muscle sections from dogs H48 and M14, the two dogs with 
signs of muscle inflammation, showed minimal presence of CD4+ 
and CD8+ T-cells in muscle; some positive staining for leukocytes 
(CD45) was present in dog H48 (Supplementary Figure S1).
dIscussIon
Muscle is an important target tissue for gene transfer–based thera-
pies for neuromuscular, metabolic, and hemorrhagic diseases. For 
HB, achieving safe, effective gene transfer in skeletal muscle would 
afford a therapeutic alternative to those patients with advanced 
liver disease due to hepatitis C contracted from plasma-derived 
coagulation concentrates. In this work, we present the first com-
plete characterization of the safety profile of a novel route of vector 
administration to muscle in a large cohort of immunocompetent, 
outbred dogs with HB.
Regardless of the route of administration and the serotype 
used, we documented a robust humoral response to the AAV 
capsid after gene transfer, a common finding in both i.m. or sys-
temic vector administration studies in experimental models and 
humans. To the limit of sensitivity of the ELISpot assay used in 
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this study,38 we did not detect any capsid-specific T-cell response. 
These results also agree with several other published studies in 
which the lack of cellular immunity to the AAV capsid was docu-
mented in the context of preclinical studies where an AAV vector 
was delivered intravascularly to the muscle,16,39,40 with only a few 
exceptions.41,42 In particular, our results agree with a recently pub-
lished study39 in which a careful evaluation of T-cell responses to 
the AAV capsid was performed using an IFN-γ ELISpot assay and 
no T-cell response to the AAV capsid was found. Whether these 
results reflect the real absence of T-cell reactive to the AAV capsid, 
or their very low frequency in peripheral blood compared to other 
lymphoid organs25 is not clear at this point.
However, in one animal, H48, receiving the mid-dose of the 
AAV-2-cFIX vector via ATVRX, which resulted in the highest 
levels of cFIX expression of all AAV-2-injected dogs, we docu-
mented some level of muscle infiltrates and regeneration; this was 
associated with the lack of detectable T-cell responses to either the 
capsid or the transgene. Muscle infiltrates in dog H48 appeared 
to be localized in defined areas, in particular in the semi-tendi-
nosus muscle, which showed high levels of vector transduction, 
suggesting that high levels of antigen were expressed locally. The 
fact that histological changes were also documented in M14, a dog 
injected i.m. with an AAV-2-cFIX vector at a dose of 3 × 1012 vg/
kg, and that these changes were not accompanied by detection of 
T-cell responses to transgene or capsid, or loss of cFIX transgene 
expression, may indicate that there is a relationship between high 
levels of antigen expressed locally and the presence of muscle 
inflammation. Some levels of inflammation have been reported 
in the literature in experimental animals24,43 and humans6 in the 
presence of transgene expression. One possible explanation of the 
phenomenon is that reactive T cells infiltrating the muscle fail to 
clear transduced tissues.44
Another intriguing finding in our study is that we did not 
observe the same pattern of muscle infiltration in M13, the AAV-
6-cFIX ATVRX dog, which received the same vector dose as H48 
and had similar levels of cFIX expression. The fact that AAV-6 
is more efficient in diffusing through the muscle fibers, achiev-
ing more widespread transduction,45 would suggest that a more 
uniform expression of the transgene product may help preventing 
local muscle inflammation.46
In humans, T-cell responses directed to the capsid antigen 
were documented in lipoprotein lipase–deficient subjects under-
going i.m. gene transfer with an AAV-1 vector expressing lipopro-
tein lipase,27 in α1-antitrypsin (AAT)-deficient subjects receiving 
i.m. injection of an AAV-1-AAT vector,5 and in a study on AAV-1-
α-sarcoglycan in limb-girdle muscular dystrophy subjects.6
Although  it  appears  clear  that  in  humans  T-cell  responses 
to  AAV  vectors  become  readily  detectable  after  gene  transfer 
in a dose-dependent fashion, data presented here and previous 
findings indicate that several factors play a role in shaping these 
responses, including immunomodulatory properties of the trans-
gene product,47 danger signals,19 levels of antigen being expressed 
locally,17,18  or  possibly  the  silencing  of  reactive  T-cells  at  the 
local level.44 Most importantly, the systemic exposure of vector, 
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documented  by  the  biodistribution  profile  of  vector  genomes 
after  ATVRX  delivery,  and  the  detection  of  cytokines  associ-
ated with vascular damage and remodeling (danger signal), are 
elements to be taken into consideration when evaluating safety 
of intravascular delivery of AAV vectors to muscle. Given these 
considerations, AAV muscle- and liver-directed gene transfer may 
have very similar safety profiles and both may require transient 
immunomodulation.
Immune tolerance to antigens expressed in the liver has been 
well documented20,48 and relies on the induction of antigen-specific 
regulatory T-cells.2,21 In contrast, muscle is typically chosen as the 
target  tissue  for  vaccines  because  it  is  more  immunogenic  than 
other tissues. In AAV-mediated gene transfer for HB, and in protein 
replacement therapy,49 the risk of developing immune responses to 
the FIX-donated gene product varies according to the genetic back-
ground of the host.50,51 Clearance of anti-FIX antibodies or absence 
of responses to the FIX transgene product has been documented 
in some instances in AAV-FIX muscle gene transfer in mice and 
dogs;22,52 in one study, immune tolerance to FIX was described in 
mice after AAV-1 gene transfer with no involvement of regulatory 
T cells.23 Our results represent the first evidence, developed in a 
large animal model of HB, that AAV-FIX gene transfer to muscle 
is associated with the expansion of a population of CD4+FoxP3+ 
T-cells secreting large amounts of IL-10 in response to cFIX-derived 
epitopes. Although these cells seem to be detectable also at baseline 
in some dogs (perhaps reflecting previous cFIX infusions or the fact 
that cFIX is detectable in liver), muscle gene transfer seems to further 
induce their expansion. This finding may explain why the humoral 
responses observed in the context of this study were predominantly 
Th2-driven and non-neutralizing. Importantly, the ability to expand 
CD4+IL-10+FoxP3+ T-cells in vitro seemed to correlate with the 
outcome of gene transfer in terms of development of inhibitory anti-
bodies to the cFIX transgene product, with the two non-IS dogs J03 
and J62 showing no expansion of these cells. Whether IS contributes 
to the induction of this CD4+IL-10+FoxP3+ T-cells population is 
not clear; however, it should be noted that a similar phenomenon 
has been described in the past for other IS regimens.53 The identifi-
cation of a population of CD4+IL-10+FoxP3+ T-cells has implica-
tions for the design of future studies in humans in which vectors 
are administered with concurrent immunosuppression, as interfer-
ence with tolerance induction may lead to development of harm-
ful immune responses to the transgene product.2 The detection of 
vector genomes in the liver suggests that a portion of cFIX trans-
gene product measured in the bloodstream after ATVRX may have 
been produced in the liver. It is likely, however, that cytomegalovirus 
promoter-driven liver expression of the cFIX transgene, if present, 
was only transient,54 a scenario more consistent with the inhibitor 
development observed in dog J62, which would argue against liver-
induced tolerance to the transgene product.20
In summary, our work shows that intravascular administra-
tion of an AAV vector encoding cFIX to HB dogs is safe and results 
in the induction of a population of CD4+IL-10+FoxP3+ T-cells 
that have suppressor activity and may contribute to modulation 
of immune responses to the transgene product in AAV-mediated 
gene transfer. This study lays the groundwork for future studies 
aimed at translating ATVRX-mediated AAV gene transfer of FIX 
to muscle in HB subjects.
MAterIAls And MetHods
Animal procedures. Both hemostatically normal and HB dogs from the 
colony at the University of North Carolina at Chapel Hill were used in this 
study. This HB canine model is characterized by the presence of a missense 
mutation within the region of the gene encoding the catalytic domain of 
FIX, resulting in complete absence of FIX antigen or activity in plasma, 
mimicking severe human HB.31 At the time of gene transfer, all animals 
were naive for antibodies to AAV capsid, with the exception of dogs used 
in re-administration experiments. Sedated dogs were administered AAV 
vectors by either i.m. injection or ATVRX, as previously described.30 At the 
time of vector administration, all HB dogs were supplemented with pooled 
normal canine plasma at doses calculated to achieve at least 10–20% of 
normal cFIX plasma activity. Dogs received 6 weekly intravenous infusions 
of cyclophosphamide (200 mg/m2 of body surface area) starting 1 week 
before vector delivery as previously described.28 Animals were bled period-
ically to obtain plasma and PBMCs. All procedures were approved by the 
Institutional Animal Care and Use Committee at the Children’s Hospital of 
Philadelphia and the University of North Carolina at Chapel Hill.
Vector production. AAV vectors were produced by triple transfection of 
HEK293 cells followed by cesium chloride gradient–based purification 
as previously described.13 All vector preps used were devoid of empty 
capsids. Vectors were titered by dot-blot hybridization or real-time PCR; 
titers were expressed as vg/ml. An AAV expression cassette with the cFIX 
complementary DNA under transcriptional control of the cytomegalovi-
rus immediate-early enhancer–promoter, a chimeric β-globin/cytomega-
lovirus intron, and the human growth hormone polyadenylation signal13 
was used in most of the experiments in HB and normal dogs. An AAV 
“null” vector carrying an antisense copy of the β-galactosidase comple-
mentary DNA under the control of a cytomegalovirus promoter was used 
in a normal dog. Vectors were pseudotyped with either AAV-1, AAV-2, or 
AAV-6 capsids.
cFIX antigen detection. cFIX antigen levels were measured by immunoas-
say using a polyclonal matched-pair antibody set for cFIX enzyme-linked 
immunosorbent assay (Affinity Biologicals, Ancaster, Ontario, Canada) 
following manufacturer’s instructions. Serial dilutions of normal pooled 
canine plasma were used as standards. With this methodology, cFIX was 
undetectable in untreated HB animals.
Antibody assays. The presence of cFIX inhibitory antibodies was deter-
mined  as  previously  reported  by  Bethesda  assay.22  One  Bethesda  unit 
represents an amount of antibody sufficient to neutralize 50% of FIX activ-
ity. Antibody subclasses against cFIX were evaluated by enzyme-linked 
immunosorbent assay capture immunoassay. Briefly, microtiter plates were 
coated with 1 µg/ml of purified plasma-derived cFIX (Enzyme Research, 
South Bend, IN). Plates were washed and blocked for 2–4 hours with 3% 
bovine  serum  albumin  0.05%  Tween  20  in  phosphate-buffered  saline. 
Samples were diluted 1/20 or 1/40 in LowCross-Buffer (Candor Bioscience, 
Weissensberg, Germany) and incubated for 2 hours at 37 °C. Antigen-
antibody complexes were detected by 2-hour incubation at 37 °C with 
horseradish peroxidase–conjugated goat anti-dog IgG1 or sheep anti-dog 
IgG2 (Bethyl Laboratories, Montgomery, TX). Similarly, to detect antibody 
responses against viral proteins, plates were coated with serotype-specific 
AAV empty capsids at 1 µg/ml. Samples were diluted 1/200 to 1/800 in 3% 
bovine serum albumin 0.05% Tween 20 in phosphate-buffered saline and 
incubated overnight at 4 °C. In both cases, a standard curve generated by 
coating serially diluted dog reference serum with known quantities of IgGs 
(Bethyl Laboratories) was used for quantification of results.
ELISpot assays. One-color ELISpot assays were used to measure IFN-γ or 
IL-10 responses to cFIX or AAV capsid proteins in PBMCs isolated from 
AAV-treated dogs. Peptide libraries of 15-mers overlapping in sequence 
by 10 amino acids and spanning the sequence of cFIX and of the AAV 
capsid  serotype-specific  VP-1  protein  were  synthesized  (Mimotopes, 1328  www.moleculartherapy.org  vol. 18 no. 7 july 2010     
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Clayton, Australia). Peptides were arranged into a matrix as previously 
described,26  or  alternatively  assembled  into  pools  of  10–24  peptides 
each. ELISpot assays were performed as previously described.55 Briefly, a 
1/60 dilution of   anti-canine IFN-γ or anti-canine IL-10 antibody (R&D 
Systems, Minneapolis, MN) was used to coat ELISpot plates (Millipore, 
Bedford, MA) overnight at 4 °C. After blocking of free binding sites for 2 
hours, 100 μl of culture media (2-mixed leukocyte culture 4% heat-inac-
tivated fetal bovine serum20) containing the antigens were added to each 
well. Media containing a mixture of 0.05 μg/ml of phorbol 12-myristate 
13-acetate  (Sigma,  St  Louis,  MO)  and  1 μg/ml  of  ionomycin  (Sigma) 
served as positive control, while plain media served as negative control. In 
all experiments, the positive control gave a robust response (>1,000 spot-
forming units/106 PBMCs), confirming good cell viability. Cryopreserved 
PBMCs were thawed, washed, and adjusted to a concentration of 2–2.5 × 
106 cells/ml in culture media, and 100 μl of the suspension was carefully 
added to each well. Each condition was assayed in triplicate. Cultures 
were incubated for 24 hours (IFN-γ) or 48 hours (IL-10) at 37 °C, 10% 
CO2.  Plates  were  subsequently  washed,  and  a  biotinylated  anti-canine 
IFN-γ antibody or anti-canine IL-10 antibody diluted 1/60 in phosphate-
buffered saline 1% bovine serum albumin was added. Finally, plates were 
washed and developed after addition of streptavidin–alkaline phosphatase 
(Mabtech,  Cincinnati,  OH)  and  a  chromogenic  substrate  (BCIP/MBT; 
KPL, Gaithersburg, MA). The number of spots was determined using an 
ELISpot reader (CTL, Cleveland, OH) and analyzed with Immunospot 
version 3.2 software (CTL). A response was considered to be positive if the 
average number of spot-forming units per million PBMCs was at least 50 
and also thre times greater than the media control.
T-cell expansion experiments and flow cytometry. A volume of 1 × 106 
PBMCs were resuspended in ~500 μl of 4% fetal bovine serum 2-mixed 
leukocyte culture media,20 along with an equal volume and concentration 
of irradiated feeder cells, and cultured at 37 °C and 5% CO2. Irradiated 
feeder cells were from the same initial PBMC population. Peptides were 
added at a concentration of 10–50 μg/ml on day 0 to stimulate PBMCs for 
1 week. To sustain culture growth, canine IL-2 (R&D Systems) was added 
every 2 days at a 10 ng/ml concentration. On the final day, all cells were 
re-stimulated with peptide 68, and monensin was added (Golgi Stop, BD 
Biosciences, San Jose, CA) according to manufacturer’s directions. After 
a further 4–5 hours of incubation, cells were harvested into fluorescence-
activated cell sorting tubes, washed twice with FACS buffer (2% fetal 
bovine serum in phosphate-buffered saline, 0.05% sodium azide), and 
stained with anti-canine CD4-FITC (AbD Serotec, Kidlington, UK) for 
1 hour at 4 °C. Cells were washed twice with FACS buffer, then incu-
bated in Fixation/Permeabilization Buffer (eBioscience, San Diego, CA) 
for 1 hour at 4 °C. Cells were washed twice with Permeabilization Wash 
Buffer  (eBioscience),  and  incubated  in  biotin-binding  NeutrAvidin 
(Invitrogen, Carlsbad, CA) for 30 minutes at room temperature. After 
two more washes in Permeabilization Wash Buffer, cells were intracel-
lularly stained with previously conjugated anti-canine IL10-biotin (R&D 
Systems) to streptavidin–phycoerythrin (Invitrogen), along with anti-
Foxp3-APC (eBioscience) for 1 hour at 4 °C. Finally, cells were washed 
twice with Permeabilization Wash Buffer, and resuspended in 4% para-
formaldehyde. For the suppression assay, PBMCs were expanded in the 
presence of cFIX or Peptide 68 for 5 days (suppressor cells), and plated 
at a 5:1 T suppressor:T effector ratio with unexpanded autologous effec-
tor cells labeled with carboxyfluorescein succinimidyl ester (Molecular 
Probe, Invitrogen, Carlsbad, CA) to distinguish them from the suppres-
sor cell population. This was done in anti-CD3 coated plates to stimulate 
target T-cell IFN-γ production (0.5 μg/well for 96 wells), with 4 × 105 of 
expanded suppressor cells in 100 μl and 1 × 105 effector cells in 100 μl. 
Cells were incubated for 1 hour, after which monensin was added. After 
an additional 4-hour incubation at 37 °C, 5% CO2, cells were harvested 
and stained with anti-CD4 PacBlue, anti-CD8 PE, and anti-IFN-γ Alexa 
647  antibodies  (AbD  Serotec,  Kidlington,  UK).  IFN-γ  secretion  was 
measured on CFSE+CD4+ and CFSE+CD8+ T-cells. All samples were 
read on a FACS CantoII flow cytometer (BD Biosciences); data were 
analyzed using the FACS Diva Software (BD Biosciences) and Flowjo 
(Treestar, Ashland, OR).
Cytokine profile. Serum samples were analyzed at baseline and at days 1, 
3, 21, and 60 after vector delivery by multiplex assay on a Luminex 100 
instrument at the Radioimmunoassay and Biomarker core of the University 
of  Pennsylvania  with  the  Milliplex  Canine  Cytokine/Chemokine  Panel 
(Millipore, Billerica, MA) for the simultaneous detection and quantification 
of 14 canine cytokines. The sensitivity of this assay was 14.4 pg/ml for gran-
ulocyte–macrophage colony-stimulating factor, 1.6 pg/ml for keratinocyte-
derived chemokine, 6.4 pg/  ml for IL-2, 12.1 pg/ml for IL-6, 20.3 pg/ml for 
IL-8, 14.8 pg/ml for IL-15, 8.6 pg/  ml for monocyte chemotactic protein -1, 
4.4 pg/ml for IFN-γ, 2.4 pg/  ml for interferon-γ inducible protein -10, 28.8 pg/
ml for IL-4, 4.6 pg/ml for IL-7, 1.6 pg/ml for IL-10, 4.6 pg/ml for IL-18, and 
0.4 pg/ml for TNF-α.
Biodistribution. Total DNA was isolated with either QIAamp DNA Mini 
Kit (Qiagen, Valencia, CA) or MasterPureDNA Purification Kit (Epicentre 
Biotechnologies,  Madison,  WI).  Vector  genome  copy  number  in  100–
200 ng of genomic DNA was determined by quantitative real-time PCR 
with a set of primers and probe placed across a splicing junction in the 
cFIX complementary DNA. Forward primer: 5′-AAC GTC ACC CAA 
CCG CTT AA-3′; reverse primer: 5′-ATG ATG GAA CCT CCG CAG 
AA-3′;  probe:  5′-FAM-CCA  GGT  CAA  TTC  CCT  TGG  CAG  GTC 
C-Quencher-3′ (Applied Biosystems, Foster City, CA). Serial dilutions of a 
linearized plasmid bearing the cFIX expression cassette used in the study 
supplemented with 200 ng of commercially available dog genomic DNA 
(Zyagen, San Diego, CA) were used to build a reference standard.
Histology. Biopsies of muscles were obtained after vector administration. 
Muscle tissue was either fixed in 10% formalin or frozen in cooled isopen-
tane followed by liquid nitrogen. Cross-sections were stained with hema-
toxylin and eosin. For cellular infiltrate staining, muscle serial cryosections 
were incubated with an anti-CD4 monoclonal antibody (1:200 dilution; 
AbD Serotec, Oxford, UK), an anti-CD8 monoclonal antibody (1:50 dilu-
tion; AbD Serotec, Oxford, UK), or an anti-CD45 monoclonal antibody 
(1:200 dilution; AbD Serotec, Oxford, UK) followed by horseradish per-
oxidase staining. Images were obtained with an Eclipse E800 microscope 
(Nikon, Tokyo, Japan).
suPPleMentArY MAterIAl
Table S1.  Summary of IFN-γ responses monitored by antigen-specific 
ELISpot.
Figure S1.    Characterization of muscle infiltrates in dogs H48 and M14.
AcKnoWledGMents
This work was supported by a grant from the National Institute of 
Health (HL64190 to K.A.H), the Howard Hughes Medical Institute, and 
the Center for Cellular and Molecular Therapeutics at the Children’s 
Hospital of Philadelphia. We would like to acknowledge Toby Cohen 
and Annie de Groot for their collaboration with bioinformatics studies 
and Alex Tai and Yi Zhao for their assistance with AAV vectors prepara-
tion. F.M., V.R.A, J.F.W., and K.A.H. are consultants for companies that 
are developing AAV-based therapies not in the field of hemophilia or 
hold patents related to AAV gene therapy. All other authors declare no 
competing financial interests.
reFerences
1.  Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA et al. (2006). 
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-
directed gene transfer in rhesus macaques and implications for human gene therapy. 
Blood 108: 3321–3328.
2.  Mingozzi, F, Hasbrouck, NC, Basner-Tschakarjan, E, Edmonson, SA, Hui, DJ, 
Sabatino, DE et al. (2007). Modulation of tolerance to the transgene product in 
a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110: 
2334–2341.Molecular Therapy  vol. 18 no. 7 july 2010  1329
© The American Society of Gene & Cell Therapy
Safety of AAV-FIX Peripheral Vein Muscle Delivery
3.  Maguire, AM, High, KA, Auricchio, A, Wright, JF, Pierce, EA, Testa, F et al. (2009).  
Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: 
a phase 1 dose-escalation trial. Lancet 374: 1597–1605.
4.  Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). 
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) 
borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369: 
2097–2105.
5.  Brantly, ML, Chulay, JD, Wang, L, Mueller, C, Humphries, M, Spencer, LT et al. (2009). 
Sustained transgene expression despite T lymphocyte responses in a clinical trial of 
rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 106: 16363–16368.
6.  Mendell, JR, Rodino-Klapac, LR, Rosales-Quintero, X, Kota, J, Coley, BD, Galloway, 
G et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores 
α-sarcoglycan and associated proteins. Ann Neurol 66: 290–297.
7.  Muir, LA and Chamberlain, JS (2009). Emerging strategies for cell and gene therapy of 
the muscular dystrophies. Expert Rev Mol Med 11: e18.
8.  Stroes, ES, Nierman, MC, Meulenberg, JJ, Franssen, R, Twisk, J, Henny, CP et al. 
(2008). Intramuscular administration of AAV1-lipoprotein lipase S447X lowers 
triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28: 
2303–2304.
9.  Patel, H and Heathcote, EJ (2009). When to treat and the benefits of treating hepatitis 
C in patients with haemophilia. Haemophilia 15: 20–32.
10.  Larson, PJ and High, KA (2001). Gene therapy for hemophilia B: AAV-mediated 
transfer of the gene for coagulation factor IX to human muscle. Adv Exp Med Biol 489: 
45–57.
11.  Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR et al. (2003). 
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe 
hemophilia B. Blood 101: 2963–2972.
12.  Kay, MA, Manno, CS, Ragni, MV, Larson, PJ, Couto, LB, McClelland, A et al. (2000). 
Evidence for gene transfer and expression of factor IX in haemophilia B patients 
treated with an AAV vector. Nat Genet 24: 257–261.
13.  Herzog, RW, Yang, EY, Couto, LB, Hagstrom, JN, Elwell, D, Fields, PA et al. 
(1999). Long-term correction of canine hemophilia B by gene transfer of blood 
coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 
56–63.
14.  Lai, Y, Yue, Y, Liu, M, Ghosh, A, Engelhardt, JF, Chamberlain, JS et al. (2005). Efficient 
in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 
23: 1435–1439.
15.  Blankinship, MJ, Gregorevic, P and Chamberlain, JS (2006). Gene therapy strategies 
for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus 
vectors. Mol Ther 13: 241–249.
16.  Toromanoff, A, Adjali, O, Larcher, T, Hill, M, Guigand, L, Chenuaud, P et al. (2010). 
Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman 
primate skeletal muscle. Mol Ther 18: 151–160.
17.  Wang, L, Cao, O, Swalm, B, Dobrzynski, E, Mingozzi, F and Herzog, RW (2005). 
Major role of local immune responses in antibody formation to factor IX in AAV gene 
transfer. Gene Ther 12: 1453–1464.
18.  Herzog, RW, Fields, PA, Arruda, VR, Brubaker, JO, Armstrong, E, McClintock, D et al. 
(2002). Influence of vector dose on factor IX-specific T and B cell responses in muscle-
directed gene therapy. Hum Gene Ther 13: 1281–1291.
19.  Matzinger, P (2002). The danger model: a renewed sense of self. Science 296: 
301–305.
20.  Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH, Wang, Y et al. (2003). 
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic 
gene transfer. J Clin Invest 111: 1347–1356.
21.  Cao, O, Dobrzynski, E, Wang, L, Nayak, S, Mingle, B, Terhorst, C et al. (2007). 
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene 
product following hepatic in vivo gene transfer. Blood 110: 1132–1140.
22.  Arruda, VR, Schuettrumpf, J, Herzog, RW, Nichols, TC, Robinson, N, Lotfi, Y et al. 
(2004). Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and 
canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103: 
85–92.
23.  Kelly, ME, Zhuo, J, Bharadwaj, AS and Chao, H (2009). Induction of immune tolerance 
to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol 
Ther 17: 857–863.
24.  Wang, L, Dobrzynski, E, Schlachterman, A, Cao, O and Herzog, RW (2005). Systemic 
protein delivery by muscle-gene transfer is limited by a local immune response. Blood 
105: 4226–4234.
25.  Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). 
CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 
419–422.
26.  Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). 
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations 
imposed by the host immune response. Nat Med 12: 342–347.
27.  Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, 
Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in 
humans results in dose-dependent activation of capsid-specific T cells. Blood (epub 
ahead of print).
28.  Arruda, VR, Stedman, HH, Nichols, TC, Haskins, ME, Nicholson, M, Herzog, RW 
et al. (2005). Regional intravascular delivery of AAV-2-F.IX to skeletal muscle 
achieves long-term correction of hemophilia B in a large animal model. Blood 105: 
3458–3464.
29.  Arruda, VR, Stedman, HH, Haurigot, V, Buchlis, G, Baila, S, Favaro, P et al. (2010). 
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as 
a novel therapy for hemophilia B. Blood (epub ahead of print).
30.  Su, LT, Gopal, K, Wang, Z, Yin, X, Nelson, A, Kozyak, BW et al. (2005). Uniform 
scale-independent gene transfer to striated muscle after transvenular extravasation of 
vector. Circulation 112: 1780–1788.
31.  Evans, JP, Brinkhous, KM, Brayer, GD, Reisner, HM and High, KA (1989). Canine 
hemophilia B resulting from a point mutation with unusual consequences. Proc Natl 
Acad Sci USA 86: 10095–10099.
32.  De Groot, AS, Moise, L, McMurry, JA, Wambre, E, Van Overtvelt, L, Moingeon, 
P et al. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide 
“Tregitopes”. Blood 112: 3303–3311.
33.  Schober, A (2008). Chemokines in vascular dysfunction and remodeling. Arterioscler 
Thromb Vasc Biol 28: 1950–1959.
34.  Okada, M, Matsumori, A, Ono, K, Furukawa, Y, Shioi, T, Iwasaki, A et al. (1998). 
Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and 
activating factor/monocyte chemoattractant protein-1 in human endothelial cells. 
Arterioscler Thromb Vasc Biol 18: 894–901.
35.  Nathwani, AC, Gray, JT, McIntosh, J, Ng, CY, Zhou, J, Spence, Y et al. (2007). Safe and 
efficient transduction of the liver after peripheral vein infusion of self-complementary 
AAV vector results in stable therapeutic expression of human FIX in nonhuman 
primates. Blood 109: 1414–1421.
36.  Lin, SW, Hensley, SE, Tatsis, N, Lasaro, MO and Ertl, HC (2007). Recombinant adeno-
associated virus vectors induce functionally impaired transgene product-specific CD8+ 
T cells in mice. J Clin Invest 117: 3958–3970.
37.  Veron, P, Allo, V, Rivière, C, Bernard, J, Douar, AM and Masurier, C (2007). Major 
subsets of human dendritic cells are efficiently transduced by self-complementary 
adeno-associated virus vectors 1 and 2. J Virol 81: 5385–5394.
38.  Janetzki, S, Panageas, KS, Ben-Porat, L, Boyer, J, Britten, CM, Clay, TM et al.; ELISpot 
Proficiency Panel of the CVC Immune Assay Working Group. (2008). Results and 
harmonization guidelines from two large-scale international Elispot proficiency panels 
conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 
57: 303–315.
39.  Rodino-Klapac, LR, Montgomery, CL, Bremer, WG, Shontz, KM, Malik, V, 
Davis, N et al. (2010). Persistent expression of FLAG-tagged micro dystrophin in 
nonhuman primates following intramuscular and vascular delivery. Mol Ther 18: 
109–117.
40.  Rodino-Klapac, LR, Janssen, PM, Montgomery, CL, Coley, BD, Chicoine, LG, Clark, 
KR et al. (2007). A translational approach for limb vascular delivery of the micro-
dystrophin gene without high volume or high pressure for treatment of Duchenne 
muscular dystrophy. J Transl Med 5: 45.
41.  Wang, Z, Storb, R, Lee, D, Kushmerick, MJ, Chu, B, Berger, C et al. (2009). Immune 
responses to AAV in canine muscle monitored by cellular assays and noninvasive 
imaging. Mol Ther 18; 617–624.
42.  Amado, D, Mingozzi, F, Hui, D, Bennicelli, JL, Wei, Z, Chen, Y et al. (2010). Safety 
and efficacy of subretinal re-administration of a viral vector in large animals to treat 
congenital blindness. Sci Transl Med 2: 21ra16. 
43.  Wang, Z, Allen, JM, Riddell, SR, Gregorevic, P, Storb, R, Tapscott, SJ et al. (2007). 
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine 
model of Duchenne muscular dystrophy. Hum Gene Ther 18: 18–26.
44.  Velazquez, VM, Bowen, DG and Walker, CM (2009). Silencing of T lymphocytes by 
antigen-driven programmed death in recombinant adeno-associated virus vector-
mediated gene therapy. Blood 113: 538–545.
45.  Blankinship, MJ, Gregorevic, P, Allen, JM, Harper, SQ, Harper, H, Halbert, CL et al. 
(2004). Efficient transduction of skeletal muscle using vectors based on adeno-
associated virus serotype 6. Mol Ther 10: 671–678.
46.  Toromanoff, A, Chérel, Y, Guilbaud, M, Penaud-Budloo, M, Snyder, RO, Haskins, ME 
et al. (2008). Safety and efficacy of regional intravenous (r.i.) versus intramuscular 
(i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 
16: 1291–1299. 
47.  Hudig, D, Haverty, T, Fulcher, C, Redelman, D and Mendelsohn, J (1981). Inhibition 
of human natural cytotoxicity by macromolecular antiproteases. J Immunol 126: 
1569–1574.
48.  Follenzi, A, Battaglia, M, Lombardo, A, Annoni, A, Roncarolo, MG and Naldini, L 
(2004). Targeting lentiviral vector expression to hepatocytes limits transgene-specific 
immune response and establishes long-term expression of human antihemophilic 
factor IX in mice. Blood 103: 3700–3709.
49.  Oldenburg, J, Schröder, J, Brackmann, HH, Müller-Reible, C, Schwaab, R and 
Tuddenham, E (2004). Environmental and genetic factors influencing inhibitor 
development. Semin Hematol 41(1 Suppl 1): 82–88.
50.  Herzog, RW, Mount, JD, Arruda, VR, High, KA and Lothrop, CD  Jr (2001). 
Muscle-directed gene transfer and transient immune suppression result in sustained 
partial correction of canine hemophilia B caused by a null mutation. Mol Ther 4: 
192–200.
51.  Cao, O, Hoffman, BE, Moghimi, B, Nayak, S, Cooper, M, Zhou, S et al. (2009). 
Impact of the underlying mutation and the route of vector administration on 
immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17: 
1733–1742.
52.  Cohn, EF, Zhuo, J, Kelly, ME and Chao, HJ (2007). Efficient induction of immune 
tolerance to coagulation factor IX following direct intramuscular gene transfer. 
J Thromb Haemost 5: 1227–1236.
53.  Chung, DT, Korn, T, Richard, J, Ruzek, M, Kohm, AP, Miller, S et al. (2007). Anti-
thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding 
myelin antigen-specific Foxp3+ regulatory T cells. Int Immunol 19: 1003–1010.
54.  Nakai, H, Herzog, RW, Hagstrom, JN, Walter, J, Kung, SH, Yang, EY et al. (1998). 
Adeno-associated viral vector-mediated gene transfer of human blood coagulation 
factor IX into mouse liver. Blood 91: 4600–4607.
55.  Bennicelli, J, Wright, JF, Komaromy, A, Jacobs, JB, Hauck, B, Zelenaia, O et al. (2008). 
Reversal of blindness in animal models of leber congenital amaurosis using optimized 
AAV2-mediated gene transfer. Mol Ther 16: 458–465.